1. Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With HIV-1 Infection: ~5-Year Results From the LATTE-2 Study
- Author
-
Smith, Graham, Henry, W. Keith, Podzamczer Palter, Daniel, Masiá, Maria Del Mar, Bettacchi, Christopher J., Arasteh, Keikawus, Jaeger, Hans, Khuong-Josses, Marie-Aude, Montes, Maria Luisa, Stellbrink, Hans-jürgen, Yazdanpanah, Yazdan, Richmond, Gary J., Sutton, Kenneth C., Zhang, Feifan, Mccoig, Cynthia C., St. Clair, Marty H., Vandermeulen, Kati, Van Solingen-Ristea, Rodica, Smith, Kimberly Y., Margolis, David A., and Spreen, William R.
- Subjects
Immunodeficiència ,Nucleòsids ,Integrase inhibitors ,Inhibidors de la integrasa ,Immunodeficiency ,Nucleosides - Abstract
Background. In the Long-Acting Antiretroviral Treatment Enabling Trial 2 (LATTE-2) phase 2b study, long-acting (LA) injectable cabotegravir + rilpivirine dosed every 8 weeks (Q8W) or every 4 weeks (Q4W) demonstrated comparable efficacy with daily oral antiretroviral therapy (ART) through 96 weeks in ART-naive adults with human immunodeficiency virus type 1 (HIV-1). Here we report efficacy, tolerability, and safety of cabotegravir + rilpivirine LA over approximately 5 years. Methods. After 20 weeks of oral cabotegravir + abacavir/lamivudine, participants were randomized to cabotegravir + rilpivirine LA Q8W or Q4W or continue oral ART through the 96-week maintenance period. In the extension period through week 256, participants continued their current LA regimen (randomized Q8W/Q4W groups) or switched from oral ART to Q8W or Q4W LA therapy (extension-switch groups). Endpoints assessed included proportion of participants with HIV-1 RNA 1 participant. Conclusions. Cabotegravir + rilpivirine LA exhibited long-term efficacy and tolerability, demonstrating its durability as maintenance therapy for HIV-1 infection.
- Published
- 2021